+44 (0)20 3910 4640 hello@symmetron.net

Venous Thromboembolism

 

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective

Journal of Medical Economics. 2011;14(6):824-34

Authors

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M

Process

\

A

\

B

\

C

Publications in other disease areas

Atrial fibrillation

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke

Cancer

Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Idiopathic pulmonary fibrosis

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review

Psoriasis

The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Rheumatoid arthritis

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

 

Venous thromboembolism

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective